Tumors of the Skin VI. Study on Effects of Local Administration of 5-Fluorouracil in Basal Cell Carcinoma**From the Department of Dermatology and the Department of Epidemiology, Roswell Park Memorial Institute, Buffalo 3, New York. by Klein, Edmund et al.
THE JOURNAL OF INVESTIGATIVE DEiwA'roLoaT
Copyright C 1966 by The Williams & Wilkins Co.
TUMORS OF THE SKIN
Vol. 47, No. I
Printed in U.S.A.
VI. STUDY ON EFFECTS OF LOCAL ADMINIsmATI0N OF 5-FLUOROURACIL
IN BASAL CELL CArlcINo*
EDMUND KLEIN, M.D., HOWARD L. STOLL, JR., M.D., HALINA
MILGROM, M.D., HERBERT L. TRAENKLE, M.D.,
SAXON GRAHAM, Pu.D. AND
FREDERICK HELM, M.D.
In a previous double-blind placebo controlled
study (1) of the effects of topical administration
of several anti-tumor agents on solitary basal
cell carcinoma, the topical application of 5-
Fluorouracil (5-FU) produced complete tumor
regression in a statistically significant number
of lesions. Long range evaluation of tumor
resolution could not be carried out in that
study, because excision biopsy of the tumor
site 1 month after administration of the anti-
tumor agent had been done. In order to deter-
mine the more protracted results of topical
application of 5-FU to solitary basal cell carci-
noma, 36 tumors were submitted to a more ex-
tended study for prolonged follow-up rather
than excisional biopsy following administration
of the agent. The following observations were
made during the first 20 months of this study.
METHOD
The interactions of 36 nodular basal cell carci-
nomas with topically applied 5-FU were studied
by gross inspection, photography and serial histo-
logic examination in 36 patients. All lesions were
examined histologically prior to inclusion in the
study. A small amount of 20% 5-FIJt in hydro-
philic base was applied to the tumor and the site
was covered with an occlusive dressing of plastic
film and adhesive tape daily for one month. The
study sites were inspected and photographed at
1—2 week intervals during the course of the ad-
ministration of 5-FU. One month following the
cessation of the applications, the site was evalu-
ated by gross inspection and biopsy examination
for presence or absence of tumor. If no tumor was
demonstrated, the area was examined at monthly
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operation of Dr. Edward Miller, Hoffmann-La-
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intervals. If tumor was present, a second course of
topical 5-FtT was administered as above. The sites
were re-evaluated one month after cessation of the
second course of application. If no tumor was de-
tected, the area was followed at monthly intervals.
If tumor was demonstrated, the tumor was eradi-
cated by the most appropriate method (surgery,
electrosurgery, radiation therapy). In some in-
stances departures from the procedure were neces-
sary for various reasons unrelated to the investiga-
tional procedures, and these will be detailed in the
discussion of results of the study.
RESULTS
The biological changes in the basal cell car-
cinomas in this study were essentially the same
as those described in the double-blind study on
the effects of several anti-tumor agents on basal
cell carcinoma (1). An initial inflammatory re-
sponse was evident grossly and histologically
within one to two days. Superficial erosion and
ulceration usually occurred and were followed
by crust formation. Eczematization of the tu-
mor and surrounding area was not often evi-
dent. Exfoliation of the crust usually left a firm,
slightly depressed, faintly erythematous scar
(Figs. 1, 2, 3, 4).
One month after the first course of applica-
tions, 24 tumor areas were grossly and micro-
scopically negative for tumor. Of these 24
study sites 18 have remained free of tumor at
the time of this report. The 18 tumor sites have
been observed for periods up to 20 months; 6
sites have been followed up to 6 months, 10
sites for 7—12 months and 2 sites for 13—20
months. In 6 of the 24 tumor sites, which were
negative clinically and histologically one month
after completion of the initial course of 5-FU,
tumor reappeared and was confirmed histologi-
cally within the subsequent 3—10 months.
Twelve tumors were still present grossly or
histologically one month following the first
course of applications. Of the 18 tumors, which
had not undergone resolution or which had re-
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eurred, 7 were subsequently treated by standard
methods of therapy (radiation, surgery, electro-
surgery). The other 11 tumors were studied
with a second course of 5-FU. One month fol-
lowing the end of the second course, 6 sites were
negative and 5 sites were positive for tumor.
(Figs. 5, 6) Two of the 6 negative sites have
remained free of tumor for observation periods
of 5 and 16 months, respectively; the remain-
ing 4 sites developed recurrent tumor (con-
firmed histologically) within 3 to 10 months fol-
lowing termination of the second course. One of
the 5 sites whicb had been positive for tumor
at the end of the second course of applications,
Fio. 3. Same lesion as shown in fig. 1 after 4 weeks
of daily applications of 20% 5-FU cream under an
occlusive dressing.
Fio. 1. Nodular basal cell carcinoma in pre-
auricular area.
Fm. 4. Same area as shown in fig. 1 at 4 weeks
after completion of study.
subsequently became negative without further
treatment and has remained free of tumor for
the duration of the observation (5 months).
Thus three tumor sites have remained free of
tumor following the second course for observa-
tion periods of 5, 7 and 16 months, respectively.
DISCUssION
Fm. 2. Same lesion as shown in fig. 1 after 2 weeks Following the first course of application of
of daily applications of 20% 5-FU cream under an
occlusive dressing. 5-FU to 36 basal cell carcinomas, 18 tumors
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FIG. 5. Residual tumor present after 1st course of applications of 20% 5-FR cream under
occlusive dressing.
Fro. 6. Same area as shown in fig. 5. Area after completion of 2nd course of applications
of 20% 5-FR cream under occlusive dressing.
were eradicated and 18 tumors persisted or re-
curred during the observation period. The
variables which were considered as possible
factors related to tumor resolution, were the age
of the patient, the anatomical site of the tumor,
and the size of tumor. None of these factors
could be correlated with tumor resolution by
standard statistical means but some trends were
present.
The location of the tumor was considered a
possible factor in tumor resolution on the basis
ousexperiencewfleatment
of single and multiple basal cell carcinomas.
Consideration was therefore given to the possi-
bility that basal cell carcinomas on the trunk
and extremities might be eradicated more con-
sistently with 5-FR than those on the head.
Furthermore, basal cell carcinomas on certain
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parts of the head, such as the nasolabial fold
and the retro-auricular fold, might be more dif-
ficult to eradicate than tumors on the fiat sur-
faces, such as the forehead and cheek. Although
statistical significance for these hypotheses could
not be established from the data, it appears
(Table I) that certain trends are present. Of
four tumors located on areas other than the
head and neck, all four were eradicated. Of 2
tumors in the nasolabial fold and 3 hi retro-
auricular areas, 1 tumor was eradicated and 4
were not. Of 17 tumors located on a fiat sur-
face of the face, such as the forehead, temple
and cheek, 9 underwent resolution.
Size of the tumor was considered a ossible
ctor in umor eradication. All methods of
therapy previous y use or asal cell carcinoma
have produced fewer cures in large tumors than
in small tumors. Table II lists the sizes of the
tumors studied. If the tumors are divided into
two groups of lesions, smaller and larger than
15 mm. in diameter, eradication appears to
have occurred somewhat more frequently in the
smaller lesions. In the group of smaller tumors
57% were eradicated, as compared to 30% eradi-
cation of the larger lesions. By Chi square
analysis, however, the probability of this being
due to factors other than chance is 25 in 100.
Since the number of observations are relatively
small, further studies are indicated to determine
the relation between size of the lesion and reac-
tion to local chemotherapy.
A number of other factors in addition to those
considered above, may determine the interaction
between anti-tumor agents and neoplastic tissue.
The depth, to which the tumor has penetrated,
the structure of the tumor, the nature of the
blood supply and the rate of tumor growth
would be of significance.
These studies and previously reported ob-
servations, (1—10) have indicated that the action
of 5 FU and other anti-tumor agents on neo-
plastic cell populations differ from the effects on
normal skin and subcutaneous tissues. The effects
on tumors are marked, while those on normal
tissues are minimal when equivalent concen-
trations of the anti-tumor agents are adminis-
tered. Tejffiffeence iii the effects of local
sorptiofl of the agent through the_mtactiid-
mis_jogh the surface of the tunr.
These observatioi however, suggest that such
differential action may deserve further attention
TABLE I
Reaction of basal cell carcinomas to topical
5-PU at various anatomical sites
Location
Number of Tumors
eradicated persisting
Forehead
Temple
Cheek
Nose
Nasolabial fold
Upper lip
Retro-auricular
Neck
Ear
Chin
Forearm
Trunk
1
4
4
2
0
1
1
0
0
1
1
3
4
0
4
1
2
2
2
2
1
0
0
0
1
TABLE II
Rewtions of basal cell carcinomas of
various sizes to topical 5-PU
Diameter of tumor
Number of Tumors
eradicated persisting
millimeter
Less than 5
5to15
16to25
More than 25
2
13
2
1
3
8
5
2
in studies on anti-tumor therapy and on the
biology of human tumors.
It should be noted that the number of tumor
regressions was considerably lower than ex-
pected from the standard methods by which
basal cell carcinoma are managed. The recur-
rence rate, even during the relatively short pe-
riod of observation, is considerably higher than
following management by established methods.
Local chemotherapy at this stage of knowledge
is clearly not indicated for the routine clinical
management of solitary basal cell carcinoma.
These considerations, however, may not ap-
ply to the management of neoplastic lesions
in which standard therapeutic methods are
complicated by the large areas of skin involved,
such as multiple superficial basal cell carci-
nomas (11) or extensive solar or arsenical kera-
toses (5, 7). In these entities exploration of the
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potential therapeutic value of local chemo-
therapy appears to be warranted.
The presently available data on local admin-
istration of chemotherapeutic agents to Cu-
taneous neoplasms have been obtained on the
bas.is of arbitrary selection of anti-tumor agents
and arbitrary modes, frequencies and duration
of administration. The arbitrary nature of
these factors is due to inadequacy of our infor-
mation, inherent in recently initiated studies.
Further studies on transport and mechanisms
of chemical anti-tumor action which are facili-
tated by the location of tumors in the skin, may
provide information of general significance for
human tumor biology and of specific relevance
to cutaneous neoplasms in man.
SUMMARY
Exploratory studies on topical administra-
tion of 20% 5-Fluorouracil in hydrophilic base
were carried out in 36 solitary nodular basal
cell carcinomas. Under the conditions of this
study, tumor resolution lasting through an ob-
servation period of 20 months was observed in
21 study sites, although changes in the natural
course of lesions were present in all the tumors.
Topical administration of anti-tumor agents is
not suitable for clinical management of solitary
basal cell carcinoma at the present. Further
evaluation as an investigative approach in
studies on chemotherapy and tumor biology
may be warranted.
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